<DOC>
	<DOCNO>NCT01766518</DOCNO>
	<brief_summary>Efficacy safety MY-REPT capsule primary , liver transplantation recipient</brief_summary>
	<brief_title>The Study Evaluate Efficacy Safety MY-REPT Capsule Primary , Liver Transplantation Recipients ( MYLT1 )</brief_title>
	<detailed_description>Open label , Multicenter , Non-comparative Study evaluate efficacy safety MY-REPT capsule primary , liver transplantation</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patient primary liver transplantation recipient Male Female age ≥19 ≤65 Patient ABO blood type correspond Donor 's blood type Patient agreement write informed consent Patient Women childbearing potential must negative serum urine pregnancy test screen visit agreement contraception Patient secondary liver transplantation ( LT ) recipient organ transplantation recipient past current Patient multiorgan transplantation recipient Patient dualgraft transplantation recipient Patient use body artificial liver LT Cr level &gt; 2.0mg/dL screen WBC &lt; 2,000/mm3 ANC &lt; 900/mm3 PLT &lt; 30,000/mm3 screen Patient experience severe gastrointestinal disorder investigator judge man 's participation impossible Patient experience severe infection ( need treatment ) Patient Donor HIV positive Patient need treat immunosuppressant chemistry therapy Patient take immunosuppressant within 30days LT ( except take Corticosteroids Tacrolimus due protocol )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>LT</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>MMF</keyword>
</DOC>